Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo
Jayeeta Ghose(The Ohio State University), Ji Young Yoo(The University of Texas MD Anderson Cancer Center), Lawrence Boise(Emory University), Enrico Caserta(City of Hope), Mariam Murtadha(City of Hope), Craig C. Hofmeister(The Ohio State University), Vikas A. Gupta(Emory University), Ada Donà(City of Hope), Balveen Kaur(Augusta University), James F. Sanchez(City of Hope), Douglas W. Sborov(University of Utah), Benjamin G. Barwick(Emory University), Luke Russell(The Ohio State University), Alena Cristina Jaime‐Ramirez(The Ohio State University), Emine Gulsen Gunes(City Of Hope National Medical Center), Steven T. Rosen(Unknown), Amrita Krishnan(City of Hope)
Cited by 10
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
|Blood|2006|1.1k
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657